Alterity Therapeutics (PRNAD) Operating Expenses (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Operating Expenses for 11 consecutive years, with $4.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Expenses rose 35.48% year-over-year to $4.8 million; the TTM figure through Dec 2025 stood at $8.4 million (down 9.09% YoY), while the FY2025 annual figure was $12.7 million, down 100.0% from the prior year.
• Operating Expenses came in at $4.8 million for Q4 2025 at Alterity Therapeutics, up from $3.5 million in the prior quarter.
• The five-year high for Operating Expenses was $5.6 million in Q4 2023, with the low at $3.5 million in Q4 2024.
• Average Operating Expenses over 5 years is $4.6 million, with a median of $4.7 million recorded in 2022.
• Across the five-year window, Operating Expenses jumped 182.39% in 2021 and slumped 37.11% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $4.4 million in 2021, then gained by 6.18% to $4.7 million in 2022, then advanced by 20.1% to $5.6 million in 2023, then plunged by 37.11% to $3.5 million in 2024, then soared by 35.48% to $4.8 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $4.8 million, $3.5 million, and $5.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.